NASDAQ:BCLI - Brainstorm Cell Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$4.18 0.00 (0.00 %)
(As of 07/22/2018 02:41 PM ET)
Previous Close$4.18
Today's Range$4.16 - $4.2120
52-Week Range$2.88 - $5.35
Volume24,439 shs
Average Volume74,905 shs
Market Capitalization$84.64 million
P/E RatioN/A
Dividend YieldN/A
Beta2.07
Brainstorm Cell Therapeutics logoBrainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of central nervous system (CNS) adult stem cell therapies designed to address the unmet medical needs of patients with debilitating neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes a patient's own cells, which are engineered outside the body, to produce and secrete factors known to promote neuronal survival. It is developing NurOwn for various neurodegenerative diseases, including its lead indication, which is in Phase III clinical trial for the treatment of amyotrophic lateral sclerosis, as well as in preclinical trial for the treatment of multiple sclerosis, Parkinson's disease, Huntington's disease, and autism spectrum disorder. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004 to reflect its new line of business in the development of novel cell therapies for neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in New York, New York.

Receive BCLI News and Ratings via Email

Sign-up to receive the latest news and ratings for BCLI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:BCLI
CUSIPN/A
Phone201-488-0460

Debt

Debt-to-Equity RatioN/A
Current Ratio1.41
Quick Ratio1.41

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.31 per share
Price / Book13.48

Profitability

EPS (Most Recent Fiscal Year)($0.26)
Net Income$-4,950,000.00
Net MarginsN/A
Return on Equity-98.51%
Return on Assets-54.43%

Miscellaneous

Employees24
Outstanding Shares20,250,000
Market Cap$84.64

Brainstorm Cell Therapeutics (NASDAQ:BCLI) Frequently Asked Questions

What is Brainstorm Cell Therapeutics' stock symbol?

Brainstorm Cell Therapeutics trades on the NASDAQ under the ticker symbol "BCLI."

How were Brainstorm Cell Therapeutics' earnings last quarter?

Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI) released its quarterly earnings data on Monday, May, 14th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.02. View Brainstorm Cell Therapeutics' Earnings History.

When is Brainstorm Cell Therapeutics' next earnings date?

Brainstorm Cell Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, July, 23rd 2018. View Earnings Estimates for Brainstorm Cell Therapeutics.

What price target have analysts set for BCLI?

2 brokerages have issued 12-month price objectives for Brainstorm Cell Therapeutics' shares. Their forecasts range from $9.00 to $11.00. On average, they anticipate Brainstorm Cell Therapeutics' stock price to reach $10.00 in the next year. This suggests a possible upside of 139.2% from the stock's current price. View Analyst Ratings for Brainstorm Cell Therapeutics.

What is the consensus analysts' recommendation for Brainstorm Cell Therapeutics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Brainstorm Cell Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

What are Wall Street analysts saying about Brainstorm Cell Therapeutics stock?

Here are some recent quotes from research analysts about Brainstorm Cell Therapeutics stock:
  • 1. HC Wainwright analysts commented, "We note that Right to Try" laws exist in 38 states, today: Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Idaho, Illinois, Indiana, Iowa, Kentucky, Louisiana, Maine, Maryland, Michigan, Minnesota, Mississippi, Missouri, Montana, Nevada, New Hampshire, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, South Carolina, South Dakota, Tennessee, Texas, Utah, Virginia, West Virginia, Washington and Wyoming — but this federal bill would introduce legislation across state lines." (5/29/2018)
  • 2. Maxim Group analysts commented, "Representatives passed a Right-to-Try" bill, to give terminally ill patients (i.e. ALS) access to experimental therapies that have completed Phase I studies (safety and/or early efficacy), are still in development, but do not yet have FDA approval. In addition, patients must not be eligible for clinical trials and have exhausted all other treatment options. The national legislation is likely to be passed into law in the coming weeks." (5/25/2018)

Who are some of Brainstorm Cell Therapeutics' key competitors?

Who are Brainstorm Cell Therapeutics' key executives?

Brainstorm Cell Therapeutics' management team includes the folowing people:
  • Mr. Chaim Lebovits, Pres & CEO (Age 47)
  • Dr. Ralph Z. Kern, COO & Chief Medical Officer (Age 60)
  • Mr. Uri Yablonka, Exec. VP, Chief Bus. Officer & Director (Age 41)
  • Mr. Eyal Rubin, CFO & Treasurer (Age 42)
  • Dr. Yael Gothelf Ph.D., VP of Scientific and Regulatory Affairs

Has Brainstorm Cell Therapeutics been receiving favorable news coverage?

News coverage about BCLI stock has trended somewhat positive this week, Accern reports. The research firm ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Brainstorm Cell Therapeutics earned a news impact score of 0.07 on Accern's scale. They also assigned headlines about the biotechnology company an impact score of 46.55 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

How do I buy shares of Brainstorm Cell Therapeutics?

Shares of BCLI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Brainstorm Cell Therapeutics' stock price today?

One share of BCLI stock can currently be purchased for approximately $4.18.

How big of a company is Brainstorm Cell Therapeutics?

Brainstorm Cell Therapeutics has a market capitalization of $84.64 million. The biotechnology company earns $-4,950,000.00 in net income (profit) each year or ($0.26) on an earnings per share basis. Brainstorm Cell Therapeutics employs 24 workers across the globe.

How can I contact Brainstorm Cell Therapeutics?

Brainstorm Cell Therapeutics' mailing address is 1745 BROADWAY 17TH FLOOR, NEW YORK NY, 10019. The biotechnology company can be reached via phone at 201-488-0460 or via email at [email protected]


MarketBeat Community Rating for Brainstorm Cell Therapeutics (NASDAQ BCLI)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  152 (Vote Outperform)
Underperform Votes:  100 (Vote Underperform)
Total Votes:  252
MarketBeat's community ratings are surveys of what our community members think about Brainstorm Cell Therapeutics and other stocks. Vote "Outperform" if you believe BCLI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BCLI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.